Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 4/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.37 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | GALR2 | O43603 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL907705 | 0.89 | SLC9A1 (0.36) | SLC9A1S1PR1MAP3K12SYKPTPN11 | |
| SCHEMBL908196 | 0.89 | MAP3K12 (0.40) | SLC9A1MAP3K12PTPN11 | |
| SCHEMBL4257261 | 0.89 | MAP3K12 (0.39) | SLC9A1S1PR1MAP3K12CHRNB1CHRNB2 | |
| SCHEMBL908447 | 0.89 | CHRNB1 (0.36) | SLC9A1S1PR1MAP3K12CHRNB1CHRNB2 | |
| SCHEMBL908028 | 0.86 | HRH4 (0.36) | SLC9A1S1PR1MAP3K12PTPN11 | |
| SCHEMBL3875754 | 0.86 | TRPV1 (0.37) | SLC9A1MAP3K12 | |
| SCHEMBL3876074 | 0.84 | SCN9A (0.37) | SLC9A1MAP3K12 | |
| SCHEMBL3877628 | 0.84 | SLC9A1 (0.41) | SLC9A1ACACB | |
| SCHEMBL3989300 | 0.84 | SLC9A1 (0.37) | SLC9A1MAP3K12CHRNB1CHRNB2CHRNB4 | |
| SCHEMBL907825 | 0.84 | ACACB (0.42) | MAP3K12CHRNB1CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | SLC9A1 4039/4885S1PR1 487/4885MAP3K12 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.